31 October 2022 9:00 GMT
Depth and breadth of data underscore commitment to addressing areas of high unmet
need in cardiorenal and rare nephrology diseases
AstraZeneca will present over 60 abstracts across its industry-leading Cardiovascular, Renal and Metabolism (CVRM) portfolio and from Alexion, AstraZeneca’s Rare Disease group, at the American Society of Nephrology (ASN) Kidney Week from 3-6 November 2022 and the American Heart Association (AHA) Scientific Sessions occurring 5-7 November 2022.
With robust science across both medical congresses, AstraZeneca demonstrates its ambition to fundamentally transform cardiorenal care and advance patient outcomes by unravelling the underlying causes of disease, developing diagnostic strategies and delivering innovative, life-changing solutions for the millions of people affected by this interconnected spectrum of diseases. Additionally, Alexion will present data highlighting scientific advancements that further the understanding of complement inhibition in the treatment of rare nephrology diseases.
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “Scientific advances are revealing the connection between cardiovascular, renal and metabolic diseases, helping to drive earlier diagnosis and opportunities for integrated treatment approaches. We look forward to sharing insights across our portfolio, including our early science targeting specific disease drivers and data from both the DELIVER and DAPA-CKD Phase III trials which build on the science demonstrating the unique cardiorenal protection and mortality benefit of Farxiga.”
Farxiga in heart failure (HF) – setting a new standard in HF management
New late-breaking data from the DELIVER Phase III trial presented at AHA assess the effects of Farxiga on health status, on patients with recurrent cardiac events, the impact based on use of other therapies, on gender or race and more1-5. These data reinforce the joint 2022 guidelines issued by AHA, the American College of Cardiology (ACC) and the Heart Failure Society of America (HFSA), recommending earlier diagnosis and earlier initiation of guideline-directed medical treatment in patients with HF6. Altogether, the pooled analysis from the Phase III DELIVER and DAPA-HF trials underpins the role of Farxiga in clinical practice as a treatment that can be initiated right away while waiting for ejection fraction (EF) to be measured and that showed mortality benefit across the full EF range7.
Farxiga in chronic kidney disease (CKD) – reinforcing leadership in CKD
New subgroup data from the DAPA-CKD Phase III trial assess effect in patients with microalbuminuria, how Farxiga use impacts hospital admissions and healthcare utilisation and highlights AstraZeneca’s commitment to help prevent or slow the progression of CKD in this large patient population8-10. These data presented at ASN also support recent updates to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, which highlight the need for preventive treatment strategies that reduce the risk of adverse kidney and cardiovascular (CV) outcomes11.
REVEAL-CKD – emphasising the need for earlier diagnosis
REVEAL-CKD data also shed light on the importance of earlier diagnosis of CKD, with the prevalence of undiagnosed CKD continuing to rise. REVEAL-CKD further demonstrated that once a diagnosis was made, patients did receive timely CKD monitoring and management of their disease, leading to patient benefits12.
Lokelma – advancing proactive hyperkalaemia (HK) management
New Lokelma data from the comprehensive CRYSTALIZE evidence programme, which is poised to disrupt the current management of HK, highlight the common and detrimental effects of renin-angiotensin-aldosterone system inhibitors (RAASi) down titration and/or discontinuation, resulting in suboptimal care of patients with CKD and/or HF, as well as patient preference amongst potassium (K+) binder treatments13,14. The 2020 and 2021 KDIGO15,16, 2021 European Society of Cardiology (ESC)17 and 2022 AHA/ACC/HFSA guidelines6 recognise novel K+ binders like Lokelma as an important management option to optimise RAASi therapy, a group of medicines key to slowing progression and reducing mortality risk in patients with CKD and/or HF.
Compass Programme – highlighting the importance of earlier diagnosis in hereditary amyloid transthyretin amyloidosis (ATTR)
Findings from the Compass Programme provide important insights on genetic testing for ATTR. Amyloidosis is progressive and may be systemic, affecting different organs within the body (i.e., heart, kidneys, peripheral nerves)18.
Amyloidosis diseases can be complex, difficult to diagnose and, in many cases, fatal if left untreated19-21. AstraZeneca, in partnership with Ionis, and Alexion, are advancing multiple assets and novel science in amyloidosis, including treatments for ATTR, cardiomyopathy (CM) and polyneuropathy (PN), as well as amyloid light chain (AL) amyloidosis.
Rare nephrology – expanding our leadership in complement inhibition
Alexion will present an analysis from the global atypical hemolytic uremic syndrome (aHUS) registry involving long-term outcomes in patients who are treated with Soliris, a characterisation of patients with thrombotic microangiopathy and triggering or associated events from the aHUS registry, as well as a tool (PLASMIC score) that may aid in the diagnosis of aHUS22-24.
Alexion is also expanding its focus in rare nephrology with multiple assets in its clinical development programmes – including Ultomiris (a C5 inhibitor) and ALXN2050 (an oral factor D inhibitor) – which are being investigated as potential treatments for proliferative lupus nephritis (LN) and immunoglobulin A nephropathy (IgAN). The presentations at ASN, which include clinical trial and real-world data across several therapeutic areas, will help to advance the understanding of these rare nephrology diseases and foster scientific exchange22-26.
AstraZeneca abstracts at ASN Kidney Week 2022 include:
Lead author |
Abstract title |
Presentation details |
|---|---|---|
Lead author Farxiga |
||
Lead author Schechter M |
Abstract title Dapagliflozin effect on hospital admissions in patients with chronic kidney disease: A post hoc analysis of the DAPA-CKD trial |
Presentation details Oral Presentation CKD: Clinical Outcomes, Trials, Mechanistic Insights November 4, 2022 16:30-18:00 Session Room: W307 |
Lead author Vart P |
Abstract title Efficacy and safety of dapagliflozin in black vs. white patients with CKD |
Presentation details Poster CKD: Clinical Trials and Pharmacoepidemiology November 5, 2022 10:00-12:00 Poster #: SA-PO889 |
Lead author Vart P |
Abstract title Effects of dapagliflozin on anaemia in patients with or without type 2 diabetes: A pre-specified analysis of the DAPA-CKD trial |
Presentation details Oral Presentation High-Impact CKD Potpourri: Something for Everyone November 5, 2022 16:30-18:00 Session Room: W307 |
Lead author Jongs N |
Abstract title Consistent benefits of dapagliflozin on kidney endpoints defined by different eGFR thresholds: A prespecified analysis from DAPA-CKD |
Presentation details Poster CKD: Clinical Trials and Pharmacoepidemiology November 5, 2022 10:00-12:00 Poster #: SA-PO886 |
Lead author Davis J |
Abstract title Extrapolation of DAPA-CKD trial endpoints in a broad urine albumin creatinine ratio population |
Presentation details Poster CKD: Clinical Trials and Pharmacoepidemiology November 5, 2022 10:00-12:00 Poster #: SA-PO888 |
Lead author McEwan P |
Abstract title Translating the findings of DAPA-CKD to reductions in healthcare resource utilization from a global perspective |
Presentation details Poster CKD: Clinical Trials and Pharmacoepidemiology November 5, 2022 10:00-12:00 Poster #: SA-PO887 |
Lead author Wittbrodt E |
Abstract title Early dapagliflozin utilization for CKD treatment in the United States |
Presentation details Poster CKD: Epidemiology, Risk Factors, Prevention November 3, 2022 10:00-12:00 Poster #: TH-PO855 |
Lead author Leon SJ |
Abstract title Association between CKD progression and heart failure: A retrospective cohort study |
Presentation details Poster Hypertension and CVD: Epidemiology, Risk Factors, Prevention November 3, 2022 10:00-12:00 Poster #: TH-PO630 |
Lead author Heerspink HJ |
Abstract title Effects of dapagliflozin in patients without diabetes and with microalbuminuria: An exploratory analysis from the DAPA-CKD trial |
Presentation details Poster CKD: Clinical Trials and Pharmacoepidemiology November 5, 2022 10:00-12:00 Poster #: SA-PO885 |
Lead author Sisk R |
Abstract title A global validation of a minimal-resource pre-screening model for reduced kidney function in patients with type 2 diabetes |
Presentation details Poster Diabetic Kidney Disease: Clinical - II November 3, 2022 10:00-12:00 Poster #: SA-PO283 |
Lead author Shoichi M |
Abstract title Impact of urinary protein examination on early diagnosis of CKD: A nationwide hospital-based observational study in Japan, REAL-CKD |
Presentation details Poster CKD: Epidemiology, Risk Factors, Prevention November 3, 2022 10:00-12:00 Poster #: TH-PO883 |
Lead author Heerspink H |
Abstract title Correlation between albuminuria and echocardiographic (echo) abnormalities in individuals with type 2 diabetes (T2D): Insights from the Take Care of Me (TCoM) program |
Presentation details Poster Diabetic Kidney Disease: Clinical November 3, 2022 10:00-12:00 Poster #: TH-PO233
|
Lead author McCausland F |
Abstract title Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: Results from DELIVER |
Presentation details Poster Late-Breaking Clinical Trials (Posters) November 3, 2022 10:00-12:00 |
Lead author Dapagliflozin/Metformin |
||
Lead author Santos-Araúijo C |
Abstract title Cardiorenal syndrome and death risk in patients with heart failure or chronic kidney disease: An urgent call for action |
Presentation details Poster Hypertension and CVD: Epidemiology, Risk Factors, Prevention November 3, 2022 10:00-12:00 Poster #: TH-PO628 |
Lead author Santos-Araúijo C |
Abstract title Cardiorenal syndrome and kidney disease progression in patients with heart failure or CKD: An urgent call for action |
Presentation details Poster Hypertension and CVD: Epidemiology, Risk Factors, Prevention November 3, 2022 10:00-12:00 Poster #: TH-PO627 |
Lead author Verinurad (RDEA3170) |
||
Lead author Halperin Kuhns V |
Abstract title Urate regulates mitochondrial function in a URAT1 dependent manner in renal epithelial cells |
Presentation details Poster CKD: Pathobiology November 4, 2022 10:00-12:00 Poster #: FR-PO996 |
Lead author Lokelma |
||
Lead author Wheeler D |
Abstract title APPETIZE: Palatability of and preference for potassium binders in patients with CKD and hyperkalaemia |
Presentation details Poster Fluid, Electrolyte, and Acid-Base Disorders: Clinical November 4, 2022 10:00-12:00 Poster #: FR-PO552 |
Lead author Ni Z |
Abstract title DIALIZE China: A phase 3b study to reduce pre-dialysis hyperkalaemia with sodium zirconium cyclosilicate in Chinese subjects |
Presentation details Oral Presentation Dialysis: Patient-Centered Interventions and Outcomes November 3, 2022 16:30-18:00 Session Room: W414 |
Lead author Hsia J |
Abstract title A prospective, real-world evidence study of hyperkalaemia management decision making: Design of the TRACK study |
Presentation details Abstract Supplement Abstract published in ASN's 2022 Abstract Supplement, available here: https://www.asn-online.org/abstracts/ |
Lead author Bakris G |
Abstract title Effects of sodium zirconium cyclosilicate (SZC) on CKD progression: Rationale and design of the phase 3 STABILIZE-CKD trial |
Presentation details Poster Fluid, Electrolyte, and Acid-Base Disorders: Clinical November 4, 2022 10:00-12:00 Poster #: FR-PO550 |
Lead author Ni Z |
Abstract title Hyperkalaemia disease burden and dialysis patterns in Chinese haemodialysis patients: An interim analysis of the Precede-K study |
Presentation details Poster Hemodialysis and Frequent Dialysis: Potpourri November 5, 2022 10:00-12:00 Poster #: SA-PO311 |
Lead author Zhao X |
Abstract title Hyperkalaemia prevalence, practice pattern and mortality in Chinese haemodialysis patients: Visualize-HD study
|
Presentation details Abstract Supplement Abstract published in ASN's 2022 Abstract Supplement, available here: https://www.asn-online.org/abstracts/ |
Lead author Streja E |
Abstract title Impact of hyperkalaemia on mortality in patients with advanced kidney disease with or without haemodialysis: Implications for deferring hemodialysis initiation under value-based models |
Presentation details Poster Fluid, Electrolyte, and Acid-Base Disorders: Clinical November 4, 2022 10:00-12:00 Poster #: FR-PO544 |
Lead author Rastogi A |
Abstract title Persistent reduction in RAASi therapy following an episode of hyperkalaemia
|
Presentation details Poster Fluid, Electrolyte, and Acid-Base Disorders: Clinical November 4, 2022 10:00-12:00 Poster #: FR-PO546 |
Lead author Zhou H |
Abstract title Recurrent hyperkalaemia and renin-angiotensin-aldosterone system inhibitor (RAASi) down-titration in a US integrated healthcare system |
Presentation details Poster Fluid, Electrolyte, and Acid-Base Disorders: Clinical November 4, 2022 10:00-12:00 Poster #: FR-PO547 |
Lead author An J |
Abstract title Cardiorenal and mortality outcomes associated with renin-angiotensin-aldosterone system inhibitor (RAASi) discontinuation after new-onset hyperkalaemia |
Presentation details Poster Fluid, Electrolyte, and Acid-Base Disorders: Clinical November 4, 2022 10:00-12:00 Poster #: FR-PO548 |
Lead author Marmol F |
Abstract title Renal adaptation to increased fecal potassium excretion by sodium zirconium cyclosilicate
|
Presentation details Poster Fluid, Electrolyte, and Acid-Base Disorders: Basic November 3, 2022 10:00-12:00 Poster #: TH-PO305 |
Lead author Marmol F |
Abstract title Sodium zirconium cyclosilicate (SZC) binds ammonium (NH4+) in the GI tract
|
Presentation details Poster Fluid, Electrolyte, and Acid-Base Disorders: Basic November 3, 2022 10:00-12:00 Poster #: TH-PO304 |
Lead author Eichiro K |
Abstract title Impact of chronic potassium binder treatment on clinical outcome in patients with hyperkalaemia: A nationwide hospital-based cohort study |
Presentation details Poster November 4, 2022 10:00-12:00 Poster #: FR-PO549 |
Lead author General/Early CVRM |
||
Lead author Lal M |
Abstract title Therapeutic blocking of NPRC, a podocyte-expressed target, is kidney protective in ZSF1 rats |
Presentation details Poster Glomerular Diseases: Podocyte Biology November 4, 2022 10:00-12:00 Poster #: FR-PO696 |
Lead author Svangård N |
Abstract title Toward a model-based patient pre-selection tool to identify suspected undiagnosed albuminuria using electronic health records
|
Presentation details Abstract Supplement Abstract published in ASN's 2022 Abstract Supplement, available here: https://www.asn-online.org/abstracts/ |
Lead author Seth A |
Abstract title TWEAK-Fn14 signalling in mesangial cells drives intrarenal inflammation during CKD progression
|
Presentation details Poster CKD: Epidemiology, Risk Factors, Prevention November 3, 2022 10:00-12:00 Poster #: TH-PO891 |
Lead author Carracedo M |
Abstract title APOL1 promotes endothelial cell activation beyond the glomerulus |
Presentation details Oral Presentation Glomerular Diseases: From Bench to Bedside November 4, 2022 16:30-18:00 Session Room: W414 |
Lead author Acoba D |
Abstract title Kidney ‘pathway orphan’ genes as an untapped source of novel biology and disease understanding |
Presentation details Abstract Supplement Abstract published in ASN's 2022 Abstract Supplement, available here: https://www.asn-online.org/abstracts/ |
Lead author Woollard KJ |
Abstract title Investigating lysozyme as a mediator of tubular epithelial inflammation: An example of CKD knowledge graph target discovery and validation |
Presentation details Poster CKD: Pathobiology - I November 4, 2022 10:00-12:00 Poster #: FR-PO1008
|
Lead author Tomaz D |
Abstract title NLRP3 inflammasome inhibition decreases NETosis in AKI |
Presentation details Poster AKI: Mechanisms - II November 4, 2022 10:00-12:00 Poster #: FR-PO167 |
Lead author Zibotentan (ZD4054) |
||
Lead author Ahlström C |
Abstract title SGLT2 inhibition mitigates intravascular fluid retention driven by an endothelin A receptor antagonist
|
Presentation details Abstract Supplement Abstract published in ASN's 2022 Abstract Supplement, available here: https://www.asn-online.org/abstracts/ |
Lead author REVEAL-CKD |
||
Lead author Tangri N |
Abstract title REVEAL-CKD: Management and monitoring of patients with CKD stage 3 in France, Germany, Italy, Japan and the United States |
Presentation details Poster CKD: Epidemiology, Risk Factors, Prevention November 3, 2022 10:00-12:00 Poster #: TH-PO889 |
Lead author Tangri N |
Abstract title REVEAL CKD: Estimated glomerular filtration rate (eGFR) decline before and after a CKD diagnosis among patients with CKD stage 3 |
Presentation details Poster CKD: Epidemiology, Risk Factors, Prevention November 3, 2022 10:00-12:00 Poster #: TH-PO888 |
Lead author Global aHUS Registry |
||
Lead author Siedlecki A |
Abstract title Characterization of patients with thrombotic microangiopathy and triggering/associated events: A Global aHUS Registry analysis |
Presentation details Poster Glomerular Diseases: Clinical, Outcomes, Trials – I [PO1303-1] November 3, 2022 10:00-12:00 Poster #: TH-PO500 |
Lead author Greenbaum L |
Abstract title Long-term outcomes in eculizumab-treated patients enrolled in the global aHUS registry |
Presentation details Poster Glomerular Diseases: Clinical, Outcomes, Trials – I [PO1303-1] November 3, 2022 10:00-12:00 Poster #: TH-PO502 |
Lead author Soliris and Ultomiris |
||
Lead author Uriol M |
Abstract title PLASMIC score to aid diagnosis of atypical hemolytic uremic syndrome: A post-hoc analysis of data from C5 inhibitor trials |
Presentation details Poster Glomerular Diseases: Clinical, Outcomes, Trials – I [PO1303-1] November 3, 2022 10:00-12:00 Poster #: TH-PO501 |
Lead author Ultomiris |
||
Lead author Garlo K |
Abstract title A phase 2 study evaluating the efficacy and safety of ravulizumab in patients with immunoglobulin A nephropathy (IgAN) or proliferative lupus nephritis (LN) |
Presentation details Poster November 3, 2022 10:00-12:00 Poster #: INFO34
|
Lead author ALXN2050 |
||
Lead author Garlo K |
Abstract title A phase 2 study evaluating the efficacy and safety of ALXN2050, a complement factor D inhibitor, in patients with immunoglobulin A nephropathy (IgAN) or proliferative lupus nephritis (LN) |
Presentation details Poster November 3, 2022 10:00-12:00 Poster #: INFO33
|
ASN Kidney Week 2022 abstracts are available online.
AstraZeneca abstracts at AHA Scientific Sessions 2022 include:
Lead author |
Abstract title |
Presentation details |
|---|---|---|
Lead author Farxiga |
||
Lead author Jhund P |
Abstract title First and repeat episodes of worsening heart failure in patients with heart failure with mildly reduced and preserved ejection fraction: An analysis of Deliver |
Presentation details Oral Presentation November 6, 2022 8:36-8:46 Session Room: N230B |
Lead author Bhatt A |
Abstract title Impact of Coronavirus Disease-2019 on participants in DELIVER |
Presentation details Oral Presentation Evolving Science in COVID-19 November 7, 2022 8:20-8:30 Session Room: Main Event III |
Lead author Kosiborod M |
Abstract title The effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and mildly reduced or preserved ejection fraction: Results from the DELIVER Trial |
Presentation details Oral Presentation A Second Look at Practice-Changing Heart Failure Trials November 7, 2022 11:00-11:08 Session Room: Main Event II |
Lead author Yang M |
Abstract title Baseline characteristics, outcomes, and treatment response to dapagliflozin in patients treated with an MRA or ARNI in DELIVER |
Presentation details Oral Presentation A Second Look at Practice-Changing Heart Failure Trials November 7, 2022 11:08-11:16 Session Room: Main Event II |
Lead author Wang X |
Abstract title Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure |
Presentation details Oral Presentation A Second Look at Practice-Changing Heart Failure Trials November 7, 2022 11:16-11:24 Session Room: Main Event II |
Lead author Butt J |
Abstract title Differences in clinical characteristics, outcomes, and treatment response to dapagliflozin across the range of ejection fraction in Black and White patients with heart failure: A pooled analysis of DAPA-HF and DELIVER |
Presentation details Oral Presentation A Second Look at Practice-Changing Heart Failure Trials November 7, 2022 11:24-11:32 Session Room: Main Event II |
Lead author Schechter M |
Abstract title The effect of dapagliflozin on hospital admissions in patients with type 2 diabetes: Post hoc analysis of the DECLARE-TIMI 58 trial |
Presentation details Virtual Poster - Available November 5-7, 2022 Poster #: VP345 |
Lead author Bozkurt B |
Abstract title Use of guideline-directed medical therapies after hospitalization for heart failure: Real-world insights from EVOLUTION HF |
Presentation details Poster Drugs, Drugs and More Drugs in Heart Failure: Impact on Outcomes November 6, 2022 10:30-11:30 Poster #: SU2153 |
Lead author Berg D |
Abstract title Serial assessment of cardiac biomarkers and risk of cardiovascular death or hospitalization for heart failure in DECLARE-TIMI 58 |
Presentation details Oral Session Advances in Diabetes and Heart Failure: From Bench to Bedside November 6, 2022 15:54-16:04 Session Room: N231 |
Lead author Chung-Lieh H |
Abstract title Clinical utilization of natriuretic peptide levels independent of WATCH-DM score for heart failure prediction in a large-scale Asian diabetic population - A multi-center cohort study |
Presentation details Virtual Poster - Available November 5-7, 2022 Poster #: VP347 |
Lead author Tsubota H |
Abstract title Machine learning models to predict development of CKD and/or HF in early stages of type 2 diabetes patients |
Presentation details Poster Predicting Incident Diabetes and Its Complications November 6, 2022 10:30-11:30 Poster #: SU3000 |
Lead author Kosiborod M |
Abstract title Prevalence and correlates of echocardiographic abnormalities in type 2 diabetes: Insights from iCaReMe Global Registry |
Presentation details Poster Mechanisms and Treatments for Heart Failure in Diabetes November 6, 2022 10:30-11:30 Poster #: SU3012 |
Lead author Gupta K |
Abstract title Health status outcomes by race in patients treated with sodium-glucose cotransporter 2 inhibitors: A pooled patient-level meta-analysis of CHIEF-HF, DEFINE-HF, and PRESERVED-HF |
Presentation details Moderated Poster November 7, 2022 10:00-10:05 Poster #: MP186 |
Lead author Brilinta |
||
Lead author Small A |
Abstract title Development of a novel polygenic risk score to predict risk of aortic stenosis events |
Presentation details Oral Presentation November 6, 2022 12:10-12:15 Poster #: 554 |
Lead author Ohman E |
Abstract title Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischemic events after PCI: Results from the TWILIGHT - Recurrent Events sub-study |
Presentation details Oral Presentation Optimal Management post PCI/ACS November 7, 2022 10:02-10:12 Session Room: Main Event III |
Lead author Eplontersen |
||
Lead author Bhatt K |
Abstract title Genetic testing for hereditary amyloid transthyretin amyloidosis: Insights from the Compass Program |
Presentation details Moderated Poster November 5, 2022 11:00-12:00 Poster #: SA2110 |
Lead author Exenatide |
||
Lead author Ostroff R |
Abstract title Cardiometabolic disease protein signatures and response to GLP-1 receptor agonist in the EXSCEL clinical trial |
Presentation details Rapid Fire Oral Presentation Understanding and Modifying Cardiovascular Risk in Diabetes November 7, 2022 13:00-13:05 Session Room: Zone 3, Science & Technology hall, Level 3 |
Lead author Peters AE |
Abstract title Proteomic pathways across ejection fraction categories in heart failure: an EXSCEL substudy |
Presentation details Poster Biomarkers in Heart Failure: Prognostic Indicators and Mechanistic Research November 6, 2022 15:45-16:45 Poster #: SU2183 |
Lead author Edmonston D |
Abstract title Metabolic profiles identify distinct cardiorenal risk factors in people with diabetes mellitus: Insights from the EXSCEL trial |
Presentation details Oral Presentation Intersection of Kidney and Heart Failure - Biomarkers, Treatment, and Outcomes in Patients with Cardiorenal Disease November 6, 2022 17:00-17:10 Session Room: S101B |
Lead author Early R&D |
||
Lead author Kardassis D |
Abstract title Safety, pharmacokinetics, and pharmacodynamics of AZD3366 alone and in combination with aspirin and ticagrelor in healthy subjects |
Presentation details Virtual Poster - Available November 5-7, 2022 Poster #: VP26 |
Lead author Varma V |
Abstract title Identification of response biomarkers and signaling pathways associated with the LOX-1 blockade by MEDI6570 in type 2 diabetes |
Presentation details Virtual Poster - Available November 5-7, 2022 Poster #: VP6 |
Lead author Hofherr A |
Abstract title The PCSK9-targeted antisense oligonucleotide AZD8233 reduces LDL-C, ApoB, and Lp(a) in patients with dyslipidemia on statin treatment - Data from the phase 2b ETESIAN study |
Presentation details Virtual Poster - Available November 5-7, 2022 Poster #: VP112 |
AHA Scientific Sessions 2022 abstracts are available online.
Notes
AstraZeneca in CVRM
Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection and improving outcomes by slowing disease progression, reducing risks and tackling co-morbidities. The Company’s ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and CV health for millions of patients worldwide.
Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
References
1. Kosiborod MN, et al. The effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and mildly reduced or preserved ejection fraction: results from the DELIVER Trial. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.
2. Jhund P, et al. First and repeat hospitalizations for heart failure in patients with heart failure with mildly reduced and preserved ejection fraction: An analysis of DELIVER. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.
3. Jhund P, et al. Baseline characteristics, outcomes, and treatment response to dapagliflozin in patients treated with an MRA or ARNI in DELIVER. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.
4. Solomon S, et al. Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: a pooled analysis of DAPA-HF and DELIVER. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.
5. Butt J, et al. Differences in clinical characteristics, outcomes, and treatment response to dapagliflozin across the range of ejection fraction in Black and White patients with heart failure: A pooled analysis of DAPA-HF and DELIVER. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.
6. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032.
7. Jhund P, et al [Internet]. Dapagliflozin and outcomes across the range of ejection fraction in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER. Nature Medicine. [cited 2022 Oct 11] Available from: https://www.nature.com/articles/s41591-022-01971-4
8. Davis J, et al. Extrapolation of DAPA-CKD trial endpoints in a broad urine albumin creatinine ratio population. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
9. Schechter M, et al. Dapagliflozin effect on hospital admissions in patients with chronic kidney disease: A post hoc analysis of the DAPA-CKD trial. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
10. McEwan P, et al. Translating the findings of DAPA-CKD to reductions in healthcare resource utilization from a global perspective. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
11. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group [Internet]. KIDGO 2022 clinical practice guideline for diabetes management in chronic kidney disease [cited 2022 Oct 11]. Available from: KDIGO-2022-Diabetes-Management-GL_Public-Review-draft_1Mar2022.pdf.
12. Tangri N, et al. REVEAL-CKD: Management and monitoring of patients with CKD stage 3 in France, Germany, Italy, Japan, and the USA. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA
13. Ni Z, et al. DIALIZE China: A phase 3b study to reduce pre-dialysis hyperkalaemia with sodium zirconium cyclosilicate in Chinese subjects. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
14. Wheeler D, et al. APPETIZE: Palatability of and preference for potassium binders in patients with chronic kidney disease and hyperkalaemia. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
15. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int Suppl. 2020;98:S1-S115.
16. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021; 99(3S):S1-S87.
17. European Society of Cardiology [Internet]. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [cited 2022 Oct 11]. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehab368.
18. Bhatt K, et al. Genetic testing for hereditary amyloid transthyretin amyloidosis: Insights from the Compass Program. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
19. NORD [Internet]. Amyloidosis [cited 2022 Oct 11]. Available from: https://rarediseases.org/rare-diseases/amyloidosis/
20. Leukaemia and Lymphoma Society [Internet]. Amyloidosis fact [cited 2022 Oct 11]. Available from: https://llscorp.stg.lls.org/sites/default/files/2021-05/Amyloidosis_FINAL.pdf
21. Cedars Sinai [Internet]. Amyloidosis [cited 2022 Oct 11]. Available from: https://www.cedars-sinai.org/health-library/diseases-and-conditions/a/amyloidosis.html
22. Siedlecki A, et al. Characterization of patients with thrombotic microangiopathy and triggering/associated events: A global aHUS registry analysis. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
23. Greenbaum L, et al. Long-term outcomes in eculizumab-treated patients enrolled in the global aHUS registry. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
24. Uriol M, et al. PLASMIC score to aid diagnosis of aHUS: A post-hoc analysis of data from C5 inhibitor trials. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
25. Garlo K, et al. A phase 2 study evaluating the efficacy and safety of ravulizumab in patients with immunoglobulin A nephropathy (IgAN) or proliferative lupus nephritis (LN). Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
26. Garlo K, et al. A phase 2 study evaluating the efficacy and safety of ALXN2050, a complement factor D inhibitor, in patients with immunoglobulin A nephropathy (IgAN) or proliferative lupus nephritis (LN). Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.